New drug ZP9830 enters first human safety study
NCT ID NCT06682975
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety and tolerability of a new drug called ZP9830 in 124 healthy adults aged 18-45. Participants receive either the drug or a placebo, given as an injection under the skin or into a vein. The study aims to understand how the drug behaves in the body and whether it causes any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZP9830
- What could go wrong
- This is a very early Phase 1 trial in healthy people, so it cannot show whether ZP9830 works for any disease. The main goal is safety, not treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Human Drug Research
RECRUITINGLeiden, CL, 2333, Netherlands
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults